Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LY-4170156 by Eli Lilly and Co for Colorectal Cancer: Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Colorectal Cancer. According to...
LY-4170156 by Eli Lilly and Co for Cervical Cancer: Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Cervical Cancer. According to...
LY-4170156 by Eli Lilly and Co for Pancreatic Cancer: Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Pancreatic Cancer. According to...
LY-4170156 by Eli Lilly and Co for Endometrial Cancer: Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Endometrial Cancer. According to...
LY-4170156 by Eli Lilly and Co for Non-Small Cell Lung Cancer: Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Non-Small Cell Lung Cancer....
LY-4170156 by Eli Lilly and Co for Fallopian Tube Cancer: Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Fallopian Tube Cancer. According...
LY-4170156 by Eli Lilly and Co for Peritoneal Cancer: Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Peritoneal Cancer. According to...
LY-4170156 by Eli Lilly and Co for Epithelial Ovarian Cancer: Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Epithelial Ovarian Cancer. According...
LY-4170156 by Eli Lilly and Co for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
LY-4170156 is under clinical development by Eli Lilly and Co and currently in Phase I for Triple-Negative Breast Cancer (TNBC)....